Prolong Pharmaceuticals
Pharmaceutical ManufacturingNew Jersey, United States11-50 Employees
Prolong Pharmaceuticals, LLC is a pharmaceutical manufacturing company headquartered in South Plainfield, New Jersey, focused on developing therapies to address comorbidities that accompany diseases such as sickle cell disease, chemotherapy, cardiovascular disorders, diabetes, and cancer. Its lead product, SANGUINATE™, targets the comorbidities associated with sickle cell disease and hemorrhagic stroke, while the company is advancing a long-acting third-generation biologic in clinical development to treat anemia linked to chronic kidney disease and cancer chemotherapy. The organization concentrates on medical conditions that elevate mortality, healthcare costs, and reduced quality of life, with an emphasis on products that address related comorbidities. Additional candidates in its pipeline aim to treat cardiovascular- and cancer-associated secondary conditions, expanding its focus within the broader disease-related morbidity space. A recent development highlights ongoing clinical activity, including presentations related to PP-007 (HEMERA-1) in acute ischemic stroke at professional conferences in 2025 and 2023. } }max_tokens=0 } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } } }
1-888-653-2347 
support@leadiq.com 
